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Introduction
The vascular endothelial growth factor (VEGF) family of 
growth factors are important modulators of the angiogen-
esis process, mediating vascular permeability and the for-
mation of new blood vessels from the existing vasculature.1 
Discovery of the involvement of VEGF in a number of 
pathologic conditions, including neovascular age-related 
macular degeneration (AMD), diabetic retinopathy, and 
cancer, has prompted the development of several anti-
VEGF therapies for the treatment of these conditions.
The fi rst anti-VEGF therapy, pegaptanib (Macugen, OSI 
Pharmaceuticals, Melville, NY, USA, and Pfi zer, New York, 
NY, USA), was approved in Europe in 2006 for the treat-
ment of neovascular AMD, shortly followed by the approval 
of ranibizumab (Lucentis, Novartis Pharmaceuticals, Basel, 
Switzerland) for the treatment of neovascular AMD in 
2007. As yet, neither of these drugs is available in Japan; 
however, pegaptanib was granted orphan-drug status in 
2004, and regulatory fi ling was made in March 2008. This 
article discusses the current status of anti-VEGF therapy in 
Europe for the treatment of neovascular AMD, and consid-
ers the future of this exciting therapy area.
Disease Background and Epidemiology
AMD is a progressive disease of the macula and the third 
major cause of blindness worldwide.2,3 In its late stages, 
AMD results in the loss of central vision due to photorecep-
tor dysfunction caused either by geographic atrophy or by 
choroidal neovascularisation (CNV). Two distinct proc-
esses lead to this vision loss: geographic atrophy (atrophic 
or dry AMD) and CNV (neovascular, exudative, or wet 
AMD). In atrophic AMD, the choriocapillaries and associ-
ated retinal pigment epithelium atrophy, whereas in neo-
vascular AMD, new vessels grow from the choriocapillaries, 
breaching Bruch’s membrane and the retinal pigment epi-
thelium to invade the retina.4 These fenestrated and fragile 
new vessels leak fl uid, lipids, and blood, resulting in fi brous 
scarring.5 If left untreated, neovascular AMD can develop 
quickly enough to cause legal blindness within months of 
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the second eye becoming affected. Therefore, early detec-
tion, diagnosis, and treatment of CNV is essential to max-
imise the preservation of central vision, minimise the risk 
of blindness, and maintain patients’ quality of life.6
Prevalence
The Rotterdam Study assessed the prevalence of age-
related maculopathy in an elderly population in the 
Netherlands.7 Prevalence of neovascular AMD was 1.1% 
overall (0.8% in men and 1.2% in women), whereas preva-
lence of atrophic AMD was 0.6% (equally prevalent in men 
and women). Prevalence of AMD increased with age, rising 
to 11% in people aged 85 years or older.7 As the population 
of Europe ages, an increase in the number of patients with 
AMD can be expected. A recent Swiss study has estimated 
that there will be a 2.5-fold increase in the number of late 
AMD cases in Switzerland by 2050, with numbers rising 
from 37 200 cases in 2005 to 52 500 cases in 2020 and 93 200 
cases in 2050.8
Treatment Options for AMD
Until the recent introduction of anti-VEGF therapy, treat-
ment options for neovascular AMD were limited. In the 
1980s, the Macular Photocoagulation Study Group reported 
that laser treatment of extrafoveal choroidal neovascular 
lesions was benefi cial in delaying loss of vision for at least 
5 years.9,10 The introduction of photodynamic therapy (PDT) 
with verteporfi n in Europe in 2000 and Japan in 2004 further 
expanded treatment options for AMD. The Treatment of 
Age-Related Macular Degeneration with Photodynamic 
Therapy Study (TAP) reported that after 2 years of treat-
ment, 53% of patients treated with verteporfi n plus PDT 
lost fewer than 15 letters, compared with 38% of patients 
treated with placebo plus PDT. Subgroup analyses revealed 
that the benefi ts of PDT with verteporfi n were concentrated 
primarily in patients with classic CNV.11
Anti-VEGF Treatment
The exact mechanisms of the pathogenesis of neovascular 
AMD are not fully understood; however, increased expres-
sion of VEGF in the optic nerve and retina is known to 
precede retinal neovascularisation.12 VEGF mRNA levels 
have been shown to be upregulated in both clinical and 
experimental studies of CNV,13–15 and the introduction of 
VEGF to healthy eyes mimics the neovascularisation that 
is observed during the disease process.16–18
Pegaptanib (Macugen)
Pegaptanib is a specifi c nucleic acid ligand (aptamer) that 
binds to VEGF165, the most abundant of the human VEGF 
isoforms, and thereby inhibits interaction with its receptors. 
Pegaptanib is licensed in Europe for the treatment of neo-
vascular AMD and is administered by intravitreal injection 
every 6 weeks for at least 2 years.19
The VEGF Inhibition Study in Ocular Neovasculariza-
tion (VISION) clinical trials investigated the safety and 
effi cacy of pegaptanib for the treatment of neovascular 
AMD in 1190 patients over 2 years.20–22 One trial enrolled 
patients from the United States and Canada, and the other 
trial enrolled patients from Europe, Israel, Australia, and 
South America. At baseline, patients were randomised to 
one of four treatment groups (0.3, 1, or 3 mg pegaptanib, 
or sham), with treatment administered every 6 weeks for 
54 weeks (a total of nine treatments). Thereafter, patients 
receiving pegaptanib were randomised to either continue 
treatment for a second year or cease treatment. To mini-
mise the number of patients receiving sham treatment for 
2 years, at year 1 the sham group was randomised to con-
tinuing sham injections, no treatment, or one of the three 
pegaptanib doses. The primary effi cacy endpoint was the 
proportion of patients losing fewer than 15 letters of visual 
acuity at week 54. The aims of the second year of study were 
to assess the safety of the 2-year treatment with pegaptanib, 
assess the relative benefi t of 2-year treatment over 2 years 
of usual care, and determine whether a second year of treat-
ment resulted in additional benefi ts beyond the fi rst year.
In a combined analysis of the data from both trials, all 
three doses of pegaptanib were effi cacious in preventing 
loss of vision compared with sham injections across all CNV 
subtypes;20 70%, 71%, and 65% of patients receiving 0.3, 1, 
and 3 mg pegaptanib, respectively, experienced a loss of 
fewer than 15 letters of visual acuity at week 54, compared 
with 55% of patients receiving sham injections (P < 0.001, 
P < 0.001, and P = 0.03, respectively). In addition, 33%, 
37%, and 31% of patients receiving 0.3, 1, and 3 mg 
pegaptanib, respectively, maintained their vision or gained 
vision, compared with 23% of patients receiving sham injec-
tions (P = 0.003, P < 0.001, and P = 0.02, respectively).20 
Figure 1 shows the mean change in visual acuity from base-
line to week 54.
Analysis of the 2-year VISION trial data revealed that 
mean visual acuity was maintained in patients receiving 
0.3 mg pegaptanib, and the proportion of patients losing 
fewer than 15 letters of visual acuity from week 54 to week 
102 was half that (7%) of those who were assigned to 
2 years of sham injections or randomised to stop treatment 
after 1 year (14%).21 In patients who had a visual acuity of 
20/200 or better at baseline, those who were treated with 
continuous 0.3 mg pegaptanib were less likely to progress 
to legal blindness in year 2; 34% of patients at week 54 and 
35% of patients at week 102 in this group had a visual acuity 
of 20/200 or worse in the study eye. In contrast, 24% of 
patients assigned to discontinue treatment with pegaptanib 
at week 54, and 47% of patients in the sham injection group, 
had a visual acuity of 20/200 or worse at week 54, increasing 
to 38% and 55%, respectively, at week 102.21
Endophthalmitis (1.3%), traumatic injury to the lens 
(0.7%), and retinal detachment (0.6%) were the most 
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serious injection-related adverse events (AEs) reported in 
the fi rst year, with two-thirds of cases of endophthalmitis 
following protocol violations. The authors concluded that 
these rates were consistent with data in the literature for 
intravitreous injections and, therefore, the risks associated 
with the intraocular injection of pegaptanib were probably 
no worse than those associated with other intraocular treat-
ments.20 However, a protocol amendment resulted in no 
reports of endophthalmitis or traumatic injury to the lens 
in year 2.22 The 2-year results also showed that there was no 
evidence of an increase in AEs associated with systemic 
VEGF inhibition, such as hypertension, thromboembolic 
events, or serious haemorrhagic events.22 An additional 1-
year systemic safety study has confi rmed that there is no 
evidence of systemic VEGF inhibition even at doses up to 
tenfold the approved 0.3 mg.23
Ranibizumab (Lucentis)
Ranibizumab is a humanised monoclonal antibody Fab 
fragment that inhibits all fi ve human isoforms of VEGF-A, 
and was specifi cally designed for the treatment of neovas-
cular AMD.24 The MARINA (Minimally Classic/Occult 
Trial of the Anti-VEGF Antibody to Ranibizumab in the 
Treatment of Neovascular Age-Related Macular Degener-
ation) study investigated ranibizumab for the treatment of 
minimally classic or occult with no classic CNV associated 
with AMD at 96 sites in the United States.25 A total of 716 
patients were randomised equally to receive 24 monthly 
intravitreal injections of 0.3 or 0.5 mg ranibizumab, or sham 
injections. The primary effi cacy endpoint was the propor-
tion of patients losing fewer than 15 letters from baseline 
visual acuity at 12 months.
At 12 months, 94.5% of patients treated with 0.3 mg 
ranibizumab and 94.6% of those treated with 0.5 mg rani-
bizumab lost fewer than 15 letters from baseline visual 
acuity, compared with 62.2% in the sham injection group 
(P < 0.001 for the comparison of each dose with the sham 
injection group). At 24 months, 92.0%, 90.0%, and 52.9% 
of patients in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, 
and sham injection group, respectively, had lost fewer than 
15 letters of visual acuity (P < 0.001 for the comparison of 
each dose with the sham injection group). Furthermore, at 
both 12 and 24 months, approximately one-quarter of 
patients receiving 0.3 mg ranibizumab, and one-third of 
patients receiving 0.5 mg ranibizumab, had gained 15 or 
more letters in visual acuity, compared with 5.0% in the 
sham injection group at 12 months and 3.8% at 24 months. 
Figure 2A shows the mean change in visual acuity from 
baseline to month 24 in this trial. Only 0.8% of patients 
receiving 0.3 mg ranibizumab, and 1.2% of patients receiv-
ing 0.5 mg ranibizumab, had severe vision loss (lost 30 
letters or more of visual acuity), compared with 14.3% of 
patients in the sham injection group.25
There was no signifi cant difference between the three 
treatment groups in the rates of nonocular AEs. In terms 
of systemic anti-VEGF effects, the rates of hypertension 
and arterial thrombolic events were similar across groups. 
Nonocular haemorrhages were similar across all treatment 
groups in the fi rst year, but cumulative rates increased in all 
groups in the second year. At 24 months, nonocular haem-
orrhage rates were 9.2%, 8.8%, and 5.5% in the 0.3 mg 
ranibizumab, 0.5 mg ranibizumab, and sham injection 
groups, respectively; these differences were not signifi cant. 
Over the course of the study, fi ve patients who received 
ranibizumab experienced presumed endophthalmitis, and 
six patients receiving ranibizumab experienced serious 
uveitis.25
A second phase III trial (ANCHOR—Anti-VEGF Anti-
body for the Treatment of Predominantly Classic Choroidal 
Neovascularisation) compared ranibizumab with vertepor-
fi n PDT for the treatment of predominantly classic neovas-
cular AMD.26 In this study, 423 patients were randomised 
equally to receive monthly intravitreal injections of 0.3 mg 
ranibizumab or 0.5 mg ranibizumab plus sham verteporfi n 
therapy, or monthly sham injections plus active verteporfi n 
therapy. The primary endpoint was the proportion of 
patients losing fewer than 15 letters from baseline visual 
acuity at 12 months. The results of this study support the 
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Figure 1. Combined mean change 
in visual acuity from baseline to 
week 54 in the VISION clinical 
trials (P < 0.002 at every point for 
the comparison of 0.3 or 1.0 mg 
pegaptanib with sham injection at 
week 54, and P < 0.05 at every 
point for the comparison of 
3.0 mg pegaptanib with sham 
injection at all other points after 
baseline).20 From ref. 20, with 
permission. Copyright © 2004 
Massachusetts Medical Society. 
All rights reserved.
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fi ndings of MARINA, with 94.3% of patients receiving 
0.3 mg ranibizumab and 96.4% of patients receiving 0.5 mg 
ranibizumab losing fewer than 15 letters, compared with 
64.3% of patients receiving verteporfi n (P < 0.001 for each 
comparison). Visual acuity improved by at least 15 letters 
in 35.7% and 40.3% of patients in the 0.3 mg ranibizumab 
and 0.5 mg ranibizumab treatment groups, respectively, 
compared with 5.6% of patients in the verteporfi n treat-
ment group (P < 0.001 for each comparison). Figure 2B 
shows the mean change in visual acuity from baseline to 
month 24 in this trial. Presumed endophthalmitis occurred 
in two patients (1.4%) and serious uveitis in one patient 
(0.7%).26
The PIER study evaluated ranibizumab administered 
monthly for 3 months, followed by quarterly injections.27 
Using this schedule, ranibizumab provided a signifi cant 
visual acuity benefi t compared with sham treatment; 
however, treatment was less effective than the monthly 
schedule employed in MARINA and ANCHOR.27 Visual 
acuity improvements were observed during the fi rst 
3 months of the study; however, it then declined during the 
rest of the 24-month duration of the trial. A subgroup analy-
sis demonstrated that although 40% of patients retained 
their initial visual acuity gain during the maintenance phase, 
the quarterly treatment schedule was not suitable for 60% 
of patients. Therefore, more frequent monitoring and 
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Figure 2A, B. Mean change from 
baseline in visual acuity from 
baseline to month 24 in the 
MARINA (A) and ANCHOR 
(B) clinical trials. A At each 
monthly assessment, P < 0.001 for 
the comparison between each 
ranibizumab group and the 
sham injection group. On day 7, 
P = 0.006 for patients receiving 
0.3 mg ranibizumab and P = 0.003 
for patients receiving 0.5 mg 
ranibizumab.25 B P < 0.001 for all 
monthly comparisons of each 
dose of ranibizumab with verte-
porfi n photodynamic therapy.26 
From ref. 26, with permission. 
Copyright © 2006 Massachusetts 
Medical Society. All rights 
reserved.
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dosing may be necessary to identify when treatment is 
needed. To address this question, a second phase IIIb study 
(SUSTAIN) is currently evaluating the effi cacy of 0.3 or 
0.5 mg ranibizumab administered monthly for 3 consecutive 
months (loading phase), followed by monthly retreatment 
as required for 9 months.28 Further doses are administered 
if visual acuity decreases by fi ve letters or more, or central 
retinal thickness (CRT) increases by 100 μm or more. Treat-
ment was not given if visual acuity was 79 letters or more, 
or CRT was less than or equal to 225 μm. An interim analy-
sis of 69 ranibizumab-naïve patients who had completed 
their 12-month visit showed a mean increase from baseline 
of 6.8 letters and a mean decrease in CRT of 74.4 μm at 
month 12, with patients receiving a mean of 5.3 injections 
(including the three loading-phase injections). Importantly, 
these improvements were stable from month 3. Therefore, 
although these results are only preliminary, it appears that 
good effi cacy outcomes can be achieved with ranibizumab 
with a lower monthly average frequency of treatment.28
Bevacizumab
Bevacizumab is a humanised monoclonal antibody to 
VEGF, designed for intravenous administration and cur-
rently approved in Europe for the treatment of colorectal 
cancer and advanced or metastatic renal cell cancer. Beva-
cizumab is derived from the same murine antibody as 
ranibizumab; however, it has a different structure and for-
mulation and is not licensed for the treatment of AMD. 
Bevacizumab has been used on an off-label basis for the 
treatment of neovascular AMD;29,30 however, as no ran-
domised clinical trials have been conducted, there is little 
fi rm evidence of either its safety or its effi cacy in this patient 
population. In the United States, the National Eye Institute 
and the National Institute of Health are collaborating on a 
multicentre clinical trial to compare the safety and effi cacy 
of ranibizumab and bevacizumab for the treatment of neo-
vascular AMD. Likewise, in the UK, the National Health 
Service is running a similar trial. Results from these trials 
are expected in the next few years.
Switzerland
On 30 August 2006, Switzerland became the fi rst European 
country to approve Lucentis for the treatment of neovascu-
lar AMD. Although Lucentis has been fully reimbursed 
for the treatment of neovascular AMD in Switzerland since 
the beginning of 2007, treatment with Lucentis is limited 
to specialised centres and requires data monitoring for 
a national registry. The offi cial recommendations are to 
administer Lucentis by intravitreal injection once a month. 
If monthly injections are not feasible, treatment may be 
reduced to one injection every 3 months after the fi rst four 
injections, although this is not as effective.
Currently, it is estimated that Lucentis is used in Swit-
zerland in around 95% of patients receiving intravitreal 
anti-VEGF treatment for neovascular AMD. In 2007, about 
4000 patients with neovascular AMD received 12 560 
intravitreal Lucentis injections. Treatment-naïve patients 
received on average 3.99 injections during the fi rst year.
In our centre, we have performed around 2800 Lucentis 
injections since we began using it for the treatment of neo-
vascular AMD in March 2005. In the beginning, our treat-
ment regimen included three monthly injections followed 
by dosing as required. Retreatment was initiated if visual 
acuity deteriorated or lesion activity increased, as shown by 
either optical coherence tomography (OCT) or by fl uores-
cein angiography; however, using this regimen we were not 
able to reproduce the exciting results of the ANCHOR or 
MARINA studies. Therefore, we are currently using a more 
aggressive approach to treatment (Fig. 3): patients initially 
receive three monthly intravitreal injections of Lucentis, 
followed by maintenance dosage every 3 months in patients 
without active lesions and reinitiation of three monthly 
injections in patients with active lesions at follow-up visits. 
An active lesion is defi ned as new intra- or subretinal haem-
orrhages, intra- or subretinal fl uid accumulation on high-
resolution OCT, or leakage on fl uorescein angiography 
(Fig. 4). First analysis confi rms that this approach may lead 
to a better visual outcome than the previously used 
regimen.
Future of Anti-VEGF Therapy
Anti-VEGF Therapy in Combination with PDT
Both ranibizumab and pegaptanib are currently being 
investigated in combination with PDT, with the aim of 
Exudative
AMD
Active
lesion
Monthly 
Lucentis 
for 3 months
Monthly 
Lucentis 
for 3 months
Control visit
   OCT
   FA, if OCT dry
noyes
yes no
Maintenance 
dosing every 
3 months
Figure 3. Our current approach for treating patients with neovascular 
age-related macular degeneration (AMD) with Lucentis (ranibizu-
mab). OCT, optical coherence tomography; FA, fl uorescein 
angiography.
438 Jpn J Ophthalmol
 Vol 52: 433–439, 2008
potentially reducing the number of intravitreal injections 
required. A small open-label study of seven patients treated 
with PDT followed by intravitreal pegaptanib 48 h later has 
recently been reported.31 In this study, retreatment was 
indicated with pegaptanib every 6 weeks and with PDT 
every 12 weeks if fl uorescein angiography showed leakage 
or OCT detected intraretinal oedema. At 24 weeks, patients 
had an insignifi cant decrease in mean best-corrected visual 
acuity from 60.4 letters at baseline to 55.2 letters. The great-
est linear dimension increased from 1280 to 2066 mm 
(P = 0.043), and the total area of CNV increased from 1.4 
to 2.7 mm2 (P = 0.05). Although these results are generally 
poor, the authors suggested that larger-scale controlled 
studies are required to ascertain whether PDT can reduce 
the number of intravitreal injections, and which antiang-
iogenic agent would provide the most potent combination 
with PDT.31
Ranibizumab has also been investigated in combination 
with PDT. The FOCUS study was a 2-year multicentre, 
randomised, single-masked, controlled study to examine 
the safety and effi cacy of ranibizumab in combination with 
verteporfi n PDT in 162 patients with neovascular AMD.32 
Patients received monthly intravitreal ranibizumab or sham 
injections; all patients also received PDT on day 0, then 
quarterly as required. At month 24, 88% of patients receiv-
ing ranibizumab plus PDT had lost fewer than 15 letters 
of visual acuity, compared with 75% of patients receiving 
PDT alone (P < 0.05). In addition, 25% of patients in the 
combination therapy group had gained at least 15 letters, 
compared with 7% of patients treated with PDT alone 
(P < 0.05). Overall, patients receiving combination therapy 
showed less lesion growth and a larger reduction in CNV 
leakage and fl uid accumulation and required fewer PDT 
treatments than patients treated with PDT alone. The com-
bination treatment group had higher rates of endophthalmi-
tis (2.4%) and serious intraocular infl ammation (12.4%) 
than patients who received PDT alone (0% for each AE). 
The incidence of serious nonocular AEs was similar between 
the two groups.32
In conclusion, the development of anti-VEGF therapies 
has revolutionised the treatment of AMD. The vision 
improvements associated with these therapies mean that 
blindness is no longer an inevitable consequence of this 
condition. Going forward, the combination of anti-VEGF 
therapies with PDT offers the potential for decreased fre-
quency of injections or further improvement in treatment 
effi cacy. Furthermore, clinical trials of these agents in dia-
betic retinopathy and macular oedema (secondary to central 
and branch retinal vein occlusion, and diabetes mellitus) are 
also currently underway, suggesting that anti-VEGF thera-
pies may have the potential to treat other debilitating eye 
conditions.
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